CA-WORLDLY
21.5.2024 11:01:28 CEST | Business Wire | Press release
Worldly, the leading supply chain sustainability data and insights platform for the consumer goods and apparel industries, today announced the launch of Facility Data Manager (FDM) to help businesses more effectively track ongoing progress towards their decarbonization targets and make decisions that drive environmental improvements faster. As sustainability regulations such as the Corporate Sustainability Reporting Directive (CSRD) emerge globally, FDM helps brands prepare for environmental reporting requirements by providing timely primary data that aligns with regulatory frameworks.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521428850/en/
As sustainability regulations such as the Corporate Sustainability Reporting Directive (CSRD) emerge globally, Facility Data Manager helps brands prepare for environmental reporting requirements by providing timely primary data that aligns with regulatory frameworks. (Graphic: Business Wire)
Aligned with Cascale’s industry standard Higg Facility Environmental Module (FEM) — the most comprehensive assessment for environmental performance in the consumer goods industry — Worldly’s new Facility Data Manager enables manufacturing facilities to regularly share key impact data with their brand and retail partners. Brands can access quantitative data on energy, water, waste and other impacts submitted by dozens to thousands of manufacturing facilities, as frequently as monthly. With FDM, brands can see the waste, water and emissions they are uniquely responsible for within a single factory. This addresses a critical industry need for more timely, standardized, high-quality primary data and insights for assessing ongoing risks and opportunities for supply chain improvements and reporting sustainability progress.
"We are pleased to introduce Facility Data Manager as a transformative addition to Worldly’s sustainability solutions," says Scott Raskin, CEO of Worldly. “At Worldly, our goal is to help companies make clear, credible progress against their environmental and labor targets while helping them prepare and comply with important evolving regulatory requirements. This requires more actionable data and deeper collaboration between manufacturers and brands. I’m excited about the improved insights and transparency into performance, targets and progress that Facility Data Manager provides, and the new level of partnership that it enables as companies look to accelerate impact across the supply chain.”
Manufacturing facilities that complete the annual Higg FEM assessment can automatically import monthly data from FDM into Higg FEM, reducing reporting time and avoiding redundancy of work. Additionally, within FDM, facilities can track their own sustainability targets and share progress with their brand and retailer partners, enabling a new level of collaboration and transparency across the complex global supply chain.
"Strong communication with our brand partners is essential to our business,” Cecilia Chan, Chief Commercial Officer of Legend Swimwear Factory Limited, said. “Sustainability innovations like this from Worldly deepen our collaboration with brands and make it much easier for us to not only help them meet their environmental targets, but ours as well."
Facility Data Manager has been developed in alignment with the Higg FEM tool established by Cascale (formerly Sustainable Apparel Coalition) in 2011. As the most widely used standardized measurement framework within the apparel and footwear industry, the Higg Index suite of tools is available exclusively on the Worldly platform and used by 350+ brands and 40,000 facilities around the world for measuring environmental and social impact. Cascale will soon begin to engage its members through a governance process to support FDM’s adoption into the Higg Index.
“We welcome the additional data insights and synergistic opportunities provided by Worldly's Facility Data Manager," said Colin Browne, CEO of Cascale, the global nonprofit alliance empowering collaboration to drive equitable and restorative business practices in the consumer goods industry. "FDM integrates seamlessly with Cascale's Higg Facility Environmental Module to provide a clear and transparent picture of environmental impacts and help our members improve sustainability and align with relevant industry standards. It’s exactly what our industry needs to catalyze impact at scale.”
For more information about Facility Data Manager and Worldly's solutions, please visit worldly.io.
About Worldly
Worldly is the planet’s most comprehensive supply chain sustainability data and insights platform, trusted by 40,000+ major brands, retailers and manufacturers in fashion, outdoor, home goods, toys and more. Worldly uniquely collects high-resolution primary data specific to companies’ value chains, operations and products, providing insight into true impacts across carbon, water, chemistry and labor. Featuring the most comprehensive source of ESG data for global manufacturers and the largest library of materials and product impacts, Worldly empowers businesses to scale responsibility into their global operations, faster and more accurately. Hosting, connecting with, and supporting the leading industry solutions and methodologies including ZDHC, Bluesign and the Higg Index – the most widely-adopted measure of sustainability in the consumer goods industry – Worldly delivers the insights businesses need to reduce their impact, comply with emerging regulatory and financial disclosure requirements and meet the expectations of a new generation of customers. www.worldly.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521428850/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
